Peptic Ulcer Drugs Market Size, Share & COVID-19 Impact Analysis, By Drugs Type (Proton Pump Inhibitor (PPI), H2 Antagonists, Antibiotics, and Others), By Ulcer Type (Gastric Ulcer and Duodenal Ulcer), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2020-2027

The global peptic ulcer drugs market size was valued at USD 4.25 billion in 2019 and is projected to reach USD 5.13 billion by 2027, exhibiting a CAGR of 2.4% during the forecast period.

The demand for peptic ulcer drugs is growing at significant rate due to the factors such as rising prevalence of peptic ulcer, growing research and development activities due to government support and policies, and increasing adoption of triple therapy. For instance, according to a research article published by International Journal of Microbiology, peptic ulcer is one of the world’s major gastrointestinal disorders affecting about 10% of the world’s population. Peptic ulcers are the open sores that develop on the inner lining of the stomach and upper portion of the small intestine. The most common causes of these ulcers are the infection with the bacterium Helicobacter pylori and long term use of aspirin and non-steroidal anti-inflammatory drugs (NSAIDs).

COVID-19 Pandemic to have a Minimal Impact Owing to the Growing Demand for Medication Drugs

Despite the economies around the world suffering from the coronavirus outbreak, pharmaceutical companies such as AstraZeneca, Novartis AG, Takeda Pharmaceutical Ltd. are witnessing a positive growth. According to the first quarterly reports of the companies involved in this field, there is no significant impact on the sales of the drugs for the peptic ulcer. The pharmaceutical companies have significantly improved their supply chain management, enhanced the capabilities of their R&D, and invested more in their manufacturing management and quality control. Additionally, the government has relaxed regulations so that the physicians can provide the care to the patients through telemedicine. Hence, the peptic ulcer drugs revenue growth is expected to continue even in the tough conditions due to COVID-19.

LATEST TRENDS

Increasing Adoption of Over-the-counter Drugs to Propel the Market Growth

There are a wide variety of over-the-counter medications for the treatment of peptic ulcer disease. Approved over-the-counter steroidal anti-inflammatory drugs allow faster and cheaper access to healthcare which increases their adoption and popularity among the people. Many anti-peptic ulcer medications such as antacids (e.g., Rennie), H2-receptor antagonists antibiotics (e.g., Zantac), and proton pump inhibitors (ppis) (e.g., Losec) are available as over-the-counter drugs. Many pharmaceutical companies are investing in the development of OTC versions of peptic ulcer drugs, which is expected to drive the market growth in the upcoming years. For instance, in February 2018, Strides Shasun, a key player in the U.S. Ranitidine market, launched the OTC version of gastric ulcer drug Ranitidine in the country.

DRIVING FACTORS

Increasing Prevalence of Peptic Ulcer to Aid Growth

Peptic ulcer is one of the serious medical problems. According to the article published by National Center for Biotechnology Information (NCBI), it affects about 10% of the world’s population. For instance, according to a research article published by Harvard University., about 4 million people suffer from peptic ulcers in the U.S., every year The major cause of the increasing prevalence of peptic ulcers is the infection from H. Pylori bacterium and rising intake of NSAIDs among the population. Also, peptic ulcer disease is predominantly affecting the older population, with the peak incidence occurring between 55 and 65 years of age. Therefore, apart from the rising prevalence of peptic ulcer disease, a growing geriatric population is contributing to the expansion of the global market during the forecast period.

Increasing R&D Activities and Strong Pipeline of New Drugs to Fuel the Market Growth

The rising prevalence of peptic ulcer disease, globally, is propelling the key industry players to invest in the R&D activities. This results in the new drug launches for the treatment of peptic ulcer disease which has a positive impact on market growth. For instance, in November 2019, RedHill Biopharma Ltd. received USFDA approval for RHB-105 (Talicia) for the treatment of Helicobacter pylori in adults.

The conduction of clinical trials for new drugs in order to overcome the complications related to the currently available drugs is another factor likely to fuel market growth during the forecast period. For instance, according to clinicaltrails.gov, Takeda Pharmaceuticals has a drug Vonoprazan fumarate in Phase 3 trials, which is the drug of category potassium-competitive acid blockers (P-CABs) for peptic ulcer disease treatment.

RESTRAINING FACTORS

High Adverse Effects of Peptic Ulcer Drugs is likely to Hamper the Market Growth

Despite the increasing global prevalence of peptic ulcer disease, there are certain factors that are expected to hamper the growth of the global market. One such factor is the adverse effects associated with the use of peptic ulcer drugs. For instance, the side effects of proton pump inhibitors include nutritional deficiencies (magnesium, vitamin B12), increased risk of gastroenteritis, bowel upset, diarrhea, gastric ulcers and duodenal ulcers, and side effects associated with anticholinergic drugs include urine retention, dry mouth, and constipation.

Additionally, strict government regulations and patent expiration are some of the other factors that are limiting the global market expansion during the forecast period.

SEGMENTATION

By Drug Type Analysis

Antibiotics Dominated the Global Market due to High Cost and H. Pylori Infection

On the basis of drug type, the market includes proton pump inhibitors, h2 antagonists, antibiotics, and others. The antibiotics segment held a dominant peptic ulcer drugs market share of the global market in 2019. The majority of peptic ulcer disease is caused to the Helicobacter pylori infection. The first-line treatment for this infection is the triple therapy which includes two antibiotics and one proton pump inhibitor. Therefore, this leads to higher adoption of antibiotics leading to its dominance.

Proton pump inhibitors held the second position in 2019 and are expected to showcase a considerable growth with the highest CAGR during the forecast period.

By Ulcer Type Analysis

Increasing Prevalence of Duodenal Ulcer to Contribute in Dominance of Segment

Based on ulcer type, the peptic ulcer drugs market is segmented into gastric ulcer and duodenal ulcer. The duodenal ulcer segment is expected to lead the market during the forecast period. The growing prevalence of duodenal ulcers, along with the rising awareness about therapeutic launches for its treatment is some of the factors attributable to its dominance during the forecast period. For instance, in July 2019, ANI Pharmaceuticals in partnership with Appco Pharma announced the launch of generic ranitidine capsules for the treatment of duodenal ulcers.

By Distribution Channel Analysis

Rising Number of Peptic Ulcer Drugs Prescription to Spur the Hospital Pharmacies Growth

In terms of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is anticipated to have a dominant market share during the forecast period. The increase in the peptic ulcer diagnosed patient visits to the hospitals for obtaining effective treatment is the major factor contributing to its dominance. Additionally, the ease of availability of peptic ulcer drugs at the retail pharmacies is propelling the growth of the segment.

The rising popularity of online pharmacies among the population due to its ease and convenience is likely to augment the growth of the segment during the forecast period.

REGIONAL INSIGHTS

The market size in North America stood at USD 1.76 billion in 2019. The rising incidence of peptic ulcers in the U.S. is responsible for the dominance of the region. For instance, according to a research article published by Harvard University, about 4 million people suffer from peptic ulcers in the U.S., every year. Followed by North America, Europe is expected to hold the second position in the global market. This is attributable to the growing number of patients suffering from peptic ulcers, along with the rising healthcare expenditure in European countries such as the U.K., Germany, and France.

The market in Asia Pacific is expected to experience a faster growth rate owing to the improving healthcare infrastructure, rising awareness among the population, and growing prevalence of peptic ulcer disease. Latin America & the Middle East & Africa are likely to exhibit a relatively lower growth rate owing to the unmet needs of healthcare, less awareness, and a developing healthcare sector.

KEY INDUSTRY PLAYERS

Diverse Product Portfolio by AstraZeneca, Pfizer, Inc. to Aid the Global Market Growth

AstraZeneca, Pfizer, Inc. dominated the global market and will continue its dominance in the forthcoming years. Strong and diverse product portfolios, along with a strong distribution network across the globe are the factors attributable to their dominance. These key players are actively involved in research and development resulting in strong regulatory approvals. Moreover, strategic collaborations and acquisitions are also contributing to the expansion of the market. For instance, in April 2018, AstraZeneca in partnership with Daiichi Sankyo launched Nexium 10 mg and 20 mg Granules for Suspension, a proton pump inhibitor for the peptic ulcer treatment.

LIST OF KEY COMPANIES PROFILED:

• AstraZeneca (Cambridge, United Kingdom)


• Novartis AG (Basel, Switzerland)


• Pfizer Inc. (New York, United States)


• GlaxoSmithKline plc. (Brentford, United Kingdom)


• Takeda Pharmaceutical Company Limited. (Tokyo, Japan)


• Mylan Pharmaceuticals Inc. (Canonsburg, Pennsylvania, United States)


• Abbott (Illinois, United States)


• Zydus Cadila (Gujrat, India)


• Other Players

KEY INDUSTRY DEVELOPMENTS:

• May 2020- Famotidine, a popular to treat stomach ulcers is under investigation at Northwell Health in New York City as a potential cure for the coronavirus.     


• May 2020 – Researchers from the Michael E. De-Bakey Veterans Affairs Medical Center received FDA approval for the three-drug combination of omeprazole, amoxicillin, and rifabutin in one capsule, RHB-105, which effectively eradicates Helicobacter pylori infection in adults


• July 2019 – Zydus Cadila received the USFDA approval for Misoprostol tablets for the treatment of stomach ulcer.

REPORT COVERAGE

The peptic ulcer drugs market research report provides a detailed analysis of the market and focuses on key aspects such as leading companies, product types, and leading applications of the product. Besides this, the report offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the advanced market over recent years.

Report Scope & Segmentation